Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.
|Slideshows|February 12, 2020
4 Factors That Play Pivotal Roles in Alzheimer Disease Progression
Author(s)Gjumrakch Aliev, MD, PhD
At present there are no treatments to stop or delay underlying disease progression. Current prevalent therapies help to mask the symptoms, but they do not solve underlying causes. A fundamental premise for effective treatment is to make a diagnosis of Alzheimer disease at the earliest stage.
Advertisement
Advertisement
Related to this article
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5